RT Book, Section
A1 Weenig, Roger H.
A1 Pittelkow, Mark R.
A2 Kang, Sewon
A2 Amagai, Masayuki
A2 Bruckner, Anna L.
A2 Enk, Alexander H.
A2 Margolis, David J.
A2 McMichael, Amy J.
A2 Orringer, Jeffrey S.
SR Print(0)
ID 1161333047
T1 Scleredema and Scleromyxedema
T2 Fitzpatrick's Dermatology, 9e
YR 2019
FD 2019
PB McGraw-Hill Education
PP New York, NY
SN 9780071837798
LK accessmedicine.mhmedical.com/content.aspx?aid=1161333047
RD 2024/04/20
AB Skin  disorders  that  are  characterized  by  increased  mucin  content,  excessive  collagen  deposition,  or  fibrocyte  hyperplasia  are  designated  as  mucinoses,  sclerosing  disorders,  or  fibrosing  disorders,  respectively.  As  the  fibrocyte  (fibroblast)  is  the  cellular  component  of  their  pathogenesis,  these  conditions  are  aptly  viewed  as  various  forms  of  “fibropathy.”  In  some  conditions,  one  fibrocyte  product  predominates,  such  as  excessive  mucin  production  in  pretibial  myxedema  or  collagen  deposition  in  scleroderma.  In  others  conditions  there  is  a  combination  of  excessive  mucin  and  collagen  deposition  (scleredema)  or  excessive  mucin  deposition  and  fibrocyte  hyperplasia  (scleromyxedema  and  nephrogenic  systemic  fibrosis).  Hence,  the  nosology  of  some  of  these  conditions  does  not  accurately  describe  what  is  observed  histopathologically.  For  example,  “fibromyxedema”  more  accurately  depicts  the  histopathogenesis  of  scleromyxedema,  as  scleromyxedema  implies  a  combination  of  sclerosis  and  mucinosis,  which  more  accurately  describes  scleredema.